Anebulo Pharmaceuticals I... (ANEB)
1.20
0.04 (3.45%)
At close: Mar 03, 2025, 12:30 PM
Company Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction.
Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose.
The company was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals Inc.
| Country | United States |
| IPO Date | May 7, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Richard Anthony Cunningham |
Contact Details
Address: 1415 Ranch Road 620 South Lakeway, Texas United States | |
| Website | https://www.anebulo.com |
Stock Details
| Ticker Symbol | ANEB |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001815974 |
| CUSIP Number | 034569103 |
| ISIN Number | US0345691036 |
| Employer ID | 85-1170950 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Anthony Cunningham | Chief Executive Officer & Director |
| Daniel V. George | Principal Accounting Officer, Acting Chief Financial Officer & Secretary |
| Dr. Joseph F. Lawler M.D., Ph.D. | Founder & Chairman |
| Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Feb 24, 2025 | PRE 14A | Filing |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 20, 2025 | S-3 | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | 10-Q | Quarterly Report |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 12, 2025 | 8-K | Current Report |
| Dec 31, 2024 | D | Filing |
| Dec 26, 2024 | SCHEDULE 13D/A | [Amend] Filing |